Drug Approval | December 01, 2022
JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
This product is based on Osmotic Controlled Release Oral Delivery System technology
This product is based on Osmotic Controlled Release Oral Delivery System technology
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Subscribe To Our Newsletter & Stay Updated
